Confirmation of Trump's nominations for appointments is not yet assured and the Senate will vote to approve them early in ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

The relationship between climate change and infectious disease is raising questions around therapeutic innovation, logistical ...

The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.

There are currently no FDA- or EMA-approved treatment options available for any form of frontotemporal dementia.

The EC has granted approval for presentation of GSK's Menveo vaccine (MenACWY) for invasive meningococcal disease (IMD).

Trump's controversial administration nominees signal global ramifications for drug regulation, health funding and pharmaceutical investment.

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive ...

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...